Clayton Partners’s AstraZeneca AZN Stock Holding History

Clayton Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.4M	Buy	23,212 +68	+0.3%	+$12.8K	2.89%	13
2026 Q1	$4.56M	Buy	23,144 +74	+0.3%	+$14.3K	3.32%	11
2025 Q4	$4.24M	Sell	23,070 -256	-1%	-$44.9K	3.06%	11
2025 Q3	$3.58M	Sell	23,326 -48	-0.2%	-$7.26K	2.71%	17
2025 Q2	$3.27M	Sell	23,374 -2,445	-9%	-$343K	2.74%	15
2025 Q1	$3.8M	Buy	25,819 +2,847	+12%	+$412K	3.3%	10
2024 Q4	$3.01M	Sell	22,972 -142	-0.6%	-$19.9K	2.08%	21
2024 Q3	$3.6M	Sell	23,114 -157	-0.7%	-$25.3K	2.59%	17
2024 Q2	$3.63M	Buy	23,271 +4,834	+26%	+$727K	2.92%	13
2024 Q1	$2.5M	Buy	+18,437	New	+$2.44M	2.12%	22

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Clayton Partners's AZN Position: Q2 2026 in Review

Clayton Partners increased its AstraZeneca (AZN) stake by 0.29% in Q2 2026, buying an estimated $12.8K and bringing the position to 23,212 shares worth $4.4M. The position accounts for 2.89% of the portfolio, ranked #13.

Clayton Partners first reported a position in AZN in Q1 2024 and has held it in 10 quarters since. The position peaked at $4.56M in Q1 2026. 1,501 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Clayton Partners held 23,212 shares of AstraZeneca worth $4.4M as of Q2 2026.
Clayton Partners bought 68 AstraZeneca shares in Q2 2026, an estimated $12.8K.
AstraZeneca made up 2.89% of Clayton Partners's portfolio in Q2 2026, its #13 holding.
Clayton Partners first reported a position in AstraZeneca in Q1 2024 and has held it in 10 quarters since.
Clayton Partners's AstraZeneca position peaked at $4.56M in Q1 2026.
1,501 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Clayton Partners's 13F filing for Q2 2026, filed 14 Aug 2026.